AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Other Events

Story continues below

Item 8.01 Other Events.

On December21, 2016, AveXis,Inc. (the Company) issued a
press release announcing an update on its planned spinal muscular
atrophy Type 2 trial. The press release also announced
information regarding a conference call and webcast to discuss
this clinical development update. The full text of the Companys
press release regarding the announcement is filed as Exhibit99.1
to this Current Report on Form8-K and is incorporated herein by
reference.

Item 9.01 Financial Statements and
Exhibits.

(d)Exhibits

Exhibit

Number

ExhibitDescription

99.1

Press Release, dated December21, 2016, titled AveXis to Use
Commercial GMP in SMA Type 2 Study.


About AVEXIS, INC. (NASDAQ:AVXS)

AveXis, Inc., formerly Biolife Cell Bank, Inc., is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either carry a mutation in their SMN1 gene or their SMN1 genes have been deleted. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels. It also focuses to develop AVXS-101 to treat additional SMA types and other treatments for rare neurological genetic diseases.

AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information

AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session down -0.91 at 49.08 with 298,519 shares trading hands.

An ad to help with our costs